Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins

被引:92
作者
Kitchens, RL
Thompson, PA
Viriyakosol, S
O'Keefe, GE
Munford, RS
机构
[1] Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA
[2] Univ Calif San Diego, Sch Med, Dept Pathol, Vet Adm San Diego Healthcare Syst, San Diego, CA 92103 USA
[3] Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA
[4] Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX 75235 USA
关键词
D O I
10.1172/JCI200113139
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
CD14, a myeloid cell-surface receptor and soluble plasma protein, binds LPS and other microbial molecules and initiates the innate immune response to bacterial invasion. The blood concentration of soluble CD14 (sCD14) increases during the systemic response to infection. Although high sCD14 blood levels have correlated with increased risk of dying from severe sepsis, sCD14 can diminish cell responses to LPS. We show here that in human serum, sCD14 increases the rate at which cell-bound LPS is released from the monocyte surface and binds to plasma lipoproteins. This enhanced rate of LPS efflux is associated with a significant reduction in the ability of monocytes to produce cytokines in response to LPS. Serum from septic patients reduced the LPS-monocyte interaction by as much as tenfold, and depletion of sCD14 from the serum restored LPS-monocyte binding and release kinetics to near normal levels. In serum from septic patients, monocyte-bound LPS also moved more rapidly into lipoproteins, which completely neutralized the biologic activity of the LPS that bound to them. In human plasma, sCD14 thus diminishes monocyte responses to LPS by transferring cell-bound LPS to lipoproteins. Stress-related increases in plasma sCD14 levels may help prevent inflammatory responses within the blood.
引用
收藏
页码:485 / 493
页数:9
相关论文
共 34 条
[1]   AMERICAN-COLLEGE OF CHEST PHYSICIANS SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE - DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ ;
ABRAMS, JH ;
BERNARD, GR ;
BIONDI, JW ;
CALVIN, JE ;
DEMLING, R ;
FAHEY, PJ ;
FISHER, CJ ;
FRANKLIN, C ;
GORELICK, KJ ;
KELLEY, MA ;
MAKI, DG ;
MARSHALL, JC ;
MERRILL, WW ;
PRIBBLE, JP ;
RACKOW, EC ;
RODELL, TC ;
SHEAGREN, JN ;
SILVER, M ;
SPRUNG, CL ;
STRAUBE, RC ;
TOBIN, MJ ;
TRENHOLME, GM ;
WAGNER, DP ;
WEBB, CD ;
WHERRY, JC ;
WIEDEMANN, HP ;
WORTEL, CH .
CRITICAL CARE MEDICINE, 1992, 20 (06) :864-874
[2]  
Cauwels A, 1999, J IMMUNOL, V162, P4762
[3]   Adenovirus-mediated transfer of a gene encoding acyloxyacyl hydrolase (AOAH) into mice increases tissue and plasma AOAH activity [J].
Coulthard, MG ;
Swindle, J ;
Munford, RS ;
Gerard, RD ;
Meidell, RS .
INFECTION AND IMMUNITY, 1996, 64 (05) :1510-1515
[4]   PROLONGED EXPRESSION OF LIPOPOLYSACCHARIDE (LPS)-INDUCED INFLAMMATORY GENES IN WHOLE-BLOOD REQUIRES CONTINUAL EXPOSURE TO LPS [J].
DEDRICK, RL ;
CONLON, PJ .
INFECTION AND IMMUNITY, 1995, 63 (04) :1362-1368
[5]  
DORAN JE, 1994, OLD HER U M, V5, P106
[6]   Low lipid concentrations in critical illness: Implications for preventing and treating endotoxemia [J].
Gordon, BR ;
Parker, TS ;
Levine, DM ;
Saal, SD ;
Wang, JCL ;
Sloan, BJ ;
Barie, PS ;
Rubin, AL .
CRITICAL CARE MEDICINE, 1996, 24 (04) :584-589
[7]  
Hailman E, 1996, J IMMUNOL, V156, P4384
[8]  
HAZIOT A, 1994, J IMMUNOL, V152, P5868
[9]   Changes in endotoxin-binding proteins during major elective surgery: Important role for soluble CD14 in regulation of biological activity of systemic endotoxin [J].
Hiki, N ;
Berger, D ;
Dentener, MA ;
Mimura, Y ;
Buurman, MA ;
Prigl, C ;
Seidelmann, M ;
Tsuji, E ;
Kaminishi, M ;
Beger, HG .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1999, 6 (06) :844-850
[10]   Infection and inflammation-induced proatherogenic changes of lipoproteins [J].
Khovidhunkit, W ;
Memon, RA ;
Feingold, KR ;
Grunfeld, C .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 :S462-S472